Novartis cites strong sales growth for $15B Sandoz spin-off

Novartis’ board of directors has unanimously agreed to separate Sandoz as a 100 per cent spin-off with a $15 billion share buyback.

Related Keywords

Germany ,China ,Japan ,United States ,Switzerland ,American ,Swiss , ,Swiss Exchange ,Novartis ,American Depositary Receipts ,American Depositary Receipt ,Markets Amp Regulations ,Cell Amp Gene Therapies ,Bio Outsourcing ,Pin Off ,Sandoz ,Gene Therapy ,Cell Therapy ,Biosimilars ,